Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12238593 | 0.76 | CYP2C9 (0.41) | CYP1A2CYP2C19ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL12215353 | 0.76 | CNR2 (0.41) | BTKALDH1A1KDM4ECNR1CNR2 | |
| SCHEMBL12215433 | 0.76 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAP3K5CNR1CNR2 | |
| SCHEMBL12215330 | 0.74 | CYP3A4 (0.41) | BTKALDH1A1KDM4EMAP3K5CNR1 | |
| SCHEMBL12215333 | 0.74 | KDM4E (0.47) | CYP1A2ALDH1A1KDM4EHSD17B10CNR1 | |
| SCHEMBL12215338 | 0.72 | CLEC4M (0.47) | CYP1A2CYP2C19KDM4ELMNACYP3A4 | |
| SCHEMBL12215340 | 0.70 | GAA (0.43) | ALDH1A1KDM4EMAP3K5CNR1CNR2 | |
| SCHEMBL13555236 | 0.69 | CYP3A4 (0.41) | CYP1A2CYP2C19ALDH1A1KDM4ECNR1 | |
| SCHEMBL12215320 | 0.69 | CYP3A4 (0.41) | CYP1A2CYP2C19ALDH1A1KDM4ECNR1 | |
| SCHEMBL12215327 | 0.67 | CYP2C9 (0.42) | CYP1A2CYP2C19ALDH1A1KDM4EMAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039486-B2 | Viricides, immunomodulators or HIV entry inhibitors; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-20080132516-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132516-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | IDO2, IDO1, INMT | CYP1A2 151/4885CYP2C19 224/4885BTK 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.